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ABSTRACT 
 
The EU Position Statement (EUPS) expert group comprised of individuals who have been 
actively involved in the planning and execution of all the low dose computed tomography 
(LDCT) randomised controlled European screening trials. They have argued that as lung 
cancer screening with LDCT saves lives, planning for implementation needs to be started by 
the national health organisations throughout Europe. 
 
The EUPS examined the current evidence which supports the planning for the 
implementation of lung cancer screening, as well as areas which require further work. One of 
the major areas the EUPS focused on was the management of prevalent lung nodules in CT 
screening programmes, lung nodules at incident screening (newly detected) and CT-detected 
lung nodules in clinical practice should be managed with different protocols, due to different 
pre-test lung cancer probability. The EUPS provides nine recommendations and a ‘Call to 
Action’ for implementation, which is naturally dependent on the outcome of the NELSON 
trial. 
 
Clearly, the issue is how Europe can take this forward as part of the political agenda of 
individual countries, as well as that of the EU Commission. An EU policy document has been 
developed, which focuses on the key steps in the implementation of cost effective lung cancer 
screening in Europe.  
 
 
 
 
The EU Position Statement (EUPS) on lung cancer screening  argues that as lung cancer 
screening with low dose computed tomography (LDCT) saves lives, we need to start 
planning for implementation by the national health organisations throughout Europe [1]. 
Evidence from the NLST trial demonstrates 20% reduction in mortality; furthermore, 
evidence from the six European pilot trials on other aspects of screening, provides sufficient 
evidence to initiate the planning for lung cancer screening now; whilst mortality data and cost 
effectiveness data is awaited from the NELSON trial [2]. 
 
The EUPS expert group comprised of individuals who have been actively involved in the 
developmental planning and execution of all the randomised controlled European screening 
trials. The EUPS Expert group benefited from the experience of clinical trialists and all the 
clinical specialist groups actively engaged with the clinical management of lung cancer 
patients. Furthermore, many of these individuals have been instrumental in providing the 
published evidence and in the development of the relevant clinical guidelines, i.e. Brtish 
Thoracic Society (BTS) Guidelines [3]. 
 
The EUPS group, comprising experts across all of the clinical disciplines in CT lung cancer 
screening, and representing  eight countries, decided to provide leadership and direction to 
the European Policy makers on how lung cancer screening should to be taken forward. 
The EU Position Statement on lung cancer screening (EUPS) policy document published 
December 2017 in Lancet Oncology [1] provided a set of nine recommendations on how we 
should take lung cancer CT screening forward in Europe, dealing with many of the 
outstanding questions which were posed, post the 2011 NLST publication [4] [5].   
 
The EUPS examined the current evidence which supports the planning for the 
implementation of lung cancer screening, as well as areas which require further work, such as 
the identification of hard to reach individuals, the further development of risk prediction 
models, which may have to be country specific and also on the availability and training of 
Thoracic Radiologists, to support future screening programmes. One of the major areas the 
EUPS focused on was the management of prevalent lung nodules in CT screening 
programmes, lung nodules at incident screening (newly detected) and CT-detected lung 
nodules in clinical practice should be managed with different protocols, due to different pre-
test lung cancer probability. 
 
The EUPS outlined the actions which need to be undertaken by the European screening 
community prior to implementation. 
 
1. Current evidence points to the inescapable fact that Low Dose Computed 
Tomography is the only screening intervention with level one evidence for the early 
detection of lung cancer, the NLST trial data, provided evidence that the CT arm 
demonstrated  a 20% mortality reduction after 3 annual screens and 6.4 years of 
follow-up compared with three annual chest x-rays.  
2. When considering the harms and benefits of lung cancer screening, any future lung 
cancer LDCT programme has to use a validated risk stratification approach. It is 
appreciated that we don't currently have the best risk models and in the future, we 
need to consider incorporating potential biomarkers to improve their accuracy.  
3. All participants in lung cancer screening programmes should be provided with clear 
information regarding the harms and benefits, enabling them to make informed 
decisions. It was also emphasized that smoking cessation has to be incorporated into 
any future screening programme as we have good evidence that this is a ‘teachable 
moment’.  
4. There is very good evidence from current European screening trials that  semi-
automated volume and volume doubling time should be incorporated into the 
management of  CT-screen detected solid nodules . In addition, we need to ensure 
there is a quality assurance system in place. 
5. The EUPS recommend that we require National quality assurance systems, set up by 
professional bodies to ensure adherence to the required standards. 
6. The management of prevalent lung nodules in CT screening programmes, lung 
nodules at incident screening (newly detected) and CT-detected lung nodules in 
clinical practice should be managed with different protocols, due to different pre-test 
lung cancer probability.  
7. To consider whether we could utilise a risk-based approach based on the results of the 
baseline and 1st screening round results, to consider whether a subset of individuals 
could have biennial screening, thereby reducing the number of CT scans in their 
lifetime and also reduce the overall cost of the programme. The potential of using 
such an approach would have to take into account if the patient’s risk changed over 
the years and thus revert to annual screening. 
8. The EUPS provided recommendations for the management of higher risk lung 
nodules by the lung cancer MDTs. 
9. The EUPS Expert Group recommends planning for implementation of LDCT 
screening should be started throughout Europe now, as LDCT lung cancer screening 
saves lives. 
 
The issue is how Europe can take this forward, a plan of action has been drawn up (Figure 1), 
however, this needs to be part of the political agenda of individual countries as well as that of  
the EU Commission. The latter has already been undertaken and a EU policy document has 
been developed. [6], which focused on the key steps in the implementation of cost effective 
lung cancer screening in Europe.  
 The European policy outlined that there should be equity across all social groups, even the 
NLST ended up recruiting a younger and ‘health aware ‘population. The UK Accelerate, 
Coordinate, Evaluate (ACE) [7] programme, has stimulated independent groups to develop 
CT screening demonstration projects to focus on the access to the ‘hard to reach population’. 
[8]. 
 
Utilising the Regional Development funding [10], potentially the nations will have access to 
a resource allocation for lung cancer screening in Europe.  The lung cancer screening 
community in Europe are requesting specific funding to assist in the planning for 
implementation, as well as in supporting future programmes in Europe. The current European 
initiatives may provide a route to assist in this process, such as through the European Guide 
on Quality Improvement in Comprehensive Cancer Control (CANCON), which follows the 
European Partnership for Action Against Cancer (EPAAC).  CANCON has the goal of 
reducing cancer incidence by 15% by 2020.   
 
 
It is appreciated that each nation in Europe has to independently decide to implement lung 
cancer screening within their own health service, based on the implementation of current 
screening programmes in breast, colon and cervical cancer. This aligns with Decision No 
1350/2007/EC of the European Parliament and of the Council of 23 October 2007 establishing 
a second programme of Community action in the field of health (2008-2013). 
 
The EU Policy document recommended that the EU Council initiated an EU Expert Group on 
lung cancer screening which reflects the experience with the existing recommendations and 
guidelines for the three other cancers. The European Recommendations should be developed 
in association with professional groups involved in CT screening in Europe.    
 
The EUPS Call for Action provides a plank in which the clung cancer clinical community can 
start to plan the implementation of lung cancer screening. 
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